                         SEQUENCE LISTING

<110>  University of Southern California
       Rodgers, Kathleen E.
       DiZerega, Gere S.
       Lund, Brett
       Kelland, Eve
       Louie, Stan
 
<120>  Methods for Treating Multiple Sclerosis

<130>  13-1524-PCT

<150>  61/798934
<151>  2013-03-15

<160>  51    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid),
       Ala, Me2Gly, Pro, Bet, Glu(NH2), Gly, Asp(NH2) or is absent,

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  optional N-terminal H or Suc

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Arg, Lys, Ala, Orn, Ser(Ac), D-Arg or D-Lys,

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  optional N-terminal Cit or Sar

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Val, Ala, Leu, norLeu, Ile, Gly, Lys, Pro,  Acpc or Tyr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  optional N-terminal Aib

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Tyr, Tyr(PO3)2, Thr, Ser, homoSer, azaTyr, or Ala

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Ile, Ala, Leu, norLeu, Val or Gly

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is His, Arg or 6-NH2-Phe

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Pro or Ala

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Phe, Phe(Br), Ile or Tyr, excluding sequences including R4
       as a terminal Tyr group.

<400>  1

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  2

Arg Val Tyr Ile His Pro Phe 
1               5           


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  3

Val Tyr Ile His Pro Phe 
1               5       


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  4

Asp Arg Val Tyr Ile His Pro 
1               5           


<210>  5
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  5

Arg Val Tyr Ile His Pro 
1               5       


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  6

Val Tyr Ile His Pro 
1               5   


<210>  7
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  7

Ile His Pro Phe 
1               


<210>  8
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  8

Asp Arg Val Tyr Ile His 
1               5       


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  9

Asp Arg Val Tyr Ile 
1               5   


<210>  10
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  10

Asp Arg Val Tyr 
1               


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Nle

<400>  11

Arg Leu Tyr Ile His Pro Phe 
1               5           


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Nle

<400>  12

Arg Val Tyr Leu His Pro Phe 
1               5           


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  13

Asp Arg Pro Tyr Ile His Pro Phe 
1               5               


<210>  14
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Nle

<400>  14

Asp Arg Leu Tyr Ile His Pro 
1               5           


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Asp or Glu or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Arg, Lys, or Ala

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Val, Ala, Leu, norLeu, Ile, Gly, Lys, or Pro

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Tyr or homoSer

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Ile, Ala, Leu, norLeu, Val or Gly

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is His or Arg

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Pro or Ala

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Phe, Ile or is absent

<400>  15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5               


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Nle

<400>  16

Asp Arg Leu Tyr Ile 
1               5   


<210>  17
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Nle

<400>  17

Asp Arg Leu Tyr Ile His 
1               5       


<210>  18
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  18

Asp Arg Val Tyr Val His Pro Phe 
1               5               


<210>  19
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  19

Asn Arg Val Tyr Val His Pro Phe 
1               5               


<210>  20
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  20

Ala Pro Gly Asp Arg Ile Tyr Val His Pro Phe 
1               5                   10      


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  21

Glu Arg Val Tyr Ile His Pro Phe 
1               5               


<210>  22
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  22

Asp Lys Val Tyr Ile His Pro Phe 
1               5               


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  23

Asp Arg Ala Tyr Ile His Pro Phe 
1               5               


<210>  24
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  24

Asp Arg Val Thr Ile His Pro Phe 
1               5               


<210>  25
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  25

Asp Arg Val Tyr Leu His Pro Phe 
1               5               


<210>  26
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  26

Asp Arg Val Tyr Ile Arg Pro Phe 
1               5               


<210>  27
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  27

Asp Arg Val Tyr Ile His Ala Phe 
1               5               


<210>  28
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  28

Asp Arg Val Tyr Ile His Pro Tyr 
1               5               


<210>  29
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  29

Pro Arg Val Tyr Ile His Pro Phe 
1               5               


<210>  30
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  PHOSPHORYLATION

<400>  30

Asp Arg Val Tyr Ile His Pro Phe 
1               5               


<210>  31
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Nle

<400>  31

Asp Arg Leu Tyr Ile His Pro Phe 
1               5               


<210>  32
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Nle

<400>  32

Asp Arg Val Tyr Leu His Pro Phe 
1               5               


<210>  33
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  homoSer

<400>  33

Asp Arg Val Xaa Tyr Ile His Pro Phe 
1               5                   


<210>  34
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  optional N-terminal H, Citron or Sar

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Arg, Lys, Ala, Orn, Ser(Ac), D-Arg or D-Lys;

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Val, Ala, Leu, norLeu, Ile, Gly, Lys, Pro, Acpc or Tyr

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  optional N-terminal Aib

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa isTyr, Tyr(PO3)2, Thr, Ser, homoSer, azaTyr, or Ala

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Ile, Ala, Leu, norLeu, Val or Gly

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is His, Arg or 6-NH2-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is Pro or Ala

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Phe, Phe(Br), Ile or Tyr, excluding sequences including R4
       as a terminal Tyr group.

<400>  34

Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5           


<210>  35
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  optional N-terminal H, Citron, or Sar

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is Arg, Lys, Ala, Orn, Ser(Ac), D-Arg or D-Lys;

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Val, Ala, Leu, norLeu, Ile, Gly, Lys, Pro, Acpc or Tyr;

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  optional N-terminal Aib

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Ile, Ala, Leu, norLeu, Val or Gly

<400>  35

Xaa Xaa Tyr Xaa His Pro Phe 
1               5           


<210>  36
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  36

Arg Val Tyr Gly His Pro Phe 
1               5           


<210>  37
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  37

Arg Val Tyr Ala His Pro Phe 
1               5           


<210>  38
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  38

Asp Arg Val Ala Ile His Pro 
1               5           


<210>  39
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  39

Asp Arg Pro Tyr Ile His Pro 
1               5           


<210>  40
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  40

Asp Arg Lys Tyr Ile His Pro 
1               5           


<210>  41
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Nle

<400>  41

Asp Arg Tyr Ile His Pro 
1               5       


<210>  42
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  42

Asp Arg Val Tyr Ile His Pro Ile 
1               5               


<210>  43
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  43

Arg Val Ala Ile His Pro Phe 
1               5           


<210>  44
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  44

Arg Val Ala Ile His Pro Phe 
1               5           


<210>  45
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  45

Gly Arg Val Tyr Ile His Pro Phe 
1               5               


<210>  46
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Nle

<400>  46

Arg Val Tyr Leu His Pro Phe 
1               5           


<210>  47
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Acp

<400>  47

Asp Arg Xaa Tyr Ile His Pro Phe 
1               5               


<210>  48
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Orn

<400>  48

Asp Xaa Val Tyr Ile His Pro Phe 
1               5               


<210>  49
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  C-terminal Citron

<400>  49

Asp Val Tyr Ile His Pro Phe 
1               5           


<210>  50
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic

<400>  50

Asp Arg Pro Ala Ile His Pro 
1               5           


<210>  51
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  3Hyp

<400>  51

Asp Arg Pro Ala Ile His Pro 
1               5           


